Sabih Alam
Internal Medicine · Durant, OKNPI 1700346350
Payments from drug & device makers
Across 109 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$369
- Novo Nordisk$214
- Amgen$206
- Gilead$149
- Bayer$121
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$91
- plus $810 from 23 others
What the payments were for
- Food & beverage$1,960100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $369 |
| Novo Nordisk | 10 | $214 |
| Amgen | 13 | $206 |
| Gilead | 10 | $149 |
| Bayer | 1 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $91 |
| Sumitomo Pharma America, Inc. | 4 | $90 |
| GSK | 4 | $67 |
| Abbott | 3 | $65 |
| Medtronic | 4 | $60 |
| Alkermes, Inc. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $48 |
| Exact Sciences | 3 | $45 |
| Johnson & Johnson | 3 | $42 |
| Astellas Pharma US Inc | 1 | $34 |
| AstraZeneca | 2 | $30 |
| Merck | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Novartis | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$121
How this compares
$1,960 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $128,262 |
| Humira(Cf) PenAdalimumab | 12 | $81,988 |
| VraylarCariprazine Hcl | 37 | $55,564 |
| EliquisApixaban | 54 | $48,677 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $44,908 |
| JardianceEmpagliflozin | 16 | $29,195 |
| MounjaroTirzepatide | 23 | $24,050 |
| FarxigaDapagliflozin Propanediol | 25 | $23,365 |
| TrulicityDulaglutide | 14 | $17,761 |
| XareltoRivaroxaban | 16 | $17,349 |
| MyrbetriqMirabegron | 33 | $17,135 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,851 |
| JanuviaSitagliptin Phosphate | 20 | $16,517 |
| MovantikNaloxegol Oxalate | 25 | $13,133 |
| Repatha SureclickEvolocumab | 12 | $6,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $214 | $128,262107 claims |
| AbbVieVraylar | $369 | $55,56437 claims |
| GSKTrelegy Ellipta | $67 | $44,90865 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $30 | $40,21651 claims |
| Johnson & JohnsonXarelto | $42 | $17,34916 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $17,13533 claims |
| MerckJanuvia | $29 | $16,51720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Durant
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.